Irras AB is Sweden- based medical device company primarily engaged in develops and commercializes solutions that are designed to transform neurocritical care. Company focus on neurosurgical procedures, where excess cerebrospinal fluid (CSF) or toxic blood byproducts often need to be emergently drained and intracranial pressure (ICP) needs to be closely regulated.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	182M 19M 16.51M 15.41M 14.15M 26.68M 1.81B 27.15M 71.18M 903M 71.35M 69.77M 2.98B	P/E 2023	-0.73x	P/E 2024	-1.89x
Enterprise Value	396M 41.34M 35.93M 33.54M 30.79M 58.06M 3.94B 59.08M 155M 1.97B 155M 152M 6.48B	EV / Sales 2023	5.26x	EV / Sales 2024	6.82x
Free-Float	3.55%	Yield 2023 *	-	Yield 2024	-

28/06/25	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
18/06/24	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03/11/23	Irras has today its last day of trading on Nasdaq Stockholm before delisting	FW
24/10/23	IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index	CI
24/10/23	IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index	CI
23/10/23	Irras Obtains Nasdaq Approval for Delisting in Stockholm	MT
20/10/23	Irras delisted from Nasdaq Stockholm with last trading day on November 3	FW
20/10/23	Sweden's Irras Files for Delisting as Privatization Nears Completion	MT
20/10/23	IR Holding Bidco calls for compulsory acquisition in Irras - applies for delisting	FW
16/10/23	Irras Obtains Extension for SEK20 Million Loan	MT
16/10/23	Irras extends SEK 20 million short-term loan	FW
02/10/23	Bidder controls 87.9 percent of the shares in Irras after completion of takeover bid	FW
19/09/23	Set-off issue only realistic option to avoid insolvency situation - Irra Board	FW

30/06/23	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv(R)	FW
30/06/23	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv	FW
22/05/23	Irra's Q1 sales below expectations - Redeye predicts new share issue and halves fair value	FW
22/05/23	Redeye lowers motivated value for Irras to SEK 0.15 (0.30)	FW
20/02/23	Redeye reiterates motivated value for Irras, but predicts capital raising this year	FW

20/10/23	IRRAS's application for delisting has been approved and the Board of Directors has resolved not to publish the interim report for the third quarter of 2023	AQ
20/10/23	NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB	AQ
20/10/23	IR Holding Bidco Inc. requests compulsory buy-out and IRRAS applies for delisting	AQ
16/10/23	IRRAS publishes prospectus	AQ
15/10/23	IRRAS has extended maturity date for its SEK 20 million short-term loan	AQ

Manager	Title	Age	Since
Will Martin CEO	Chief Executive Officer	51	01/07/2021
Griffen Stapp DFI	Director of Finance/CFO	40	17/06/2021
Sten Gustafsson IRC	Investor Relations Contact	-	09/03/2021

IRRAS AB (publ) Stock London S.E.

Stocks

0GDW

SE0008321202

Medical Equipment, Supplies & Distribution

Valuation: IRRAS AB (publ)

Latest news : IRRAS AB (publ)

Analysts' recommendations: IRRAS AB (publ)

Press Releases: IRRAS AB (publ)

Quotes and Performance

Managers and Directors: IRRAS AB (publ)

Medical Devices & Implants

Financials

Company Profile

Director	Title	Age	Since
Kleanthis Xanthopoulos BRD	Director/Board Member	68	01/06/2015
Marios Fotiadis CHM	Chairman	53	18/08/2020
Inger Gunnel Anita Tollstadius BRD	Director/Board Member	71	01/09/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRRAS AB (PUBL)	-3.63%	-70.75%	-	-	16.9M
STRYKER CORPORATION	+4.76%	+1.32%	-9.69%	+23.79%	125B
SMITH & NEPHEW PLC	+3.32%	+3.01%	+3.50%	+6.49%	13.12B
GLAUKOS CORPORATION	+2.49%	+12.48%	+98.32%	+129.57%	9.83B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-2.80%	+1.43%	-42.58%	-66.81%	4.86B
DOUBLE MEDICAL TECHNOLOGY INC.	-1.16%	-3.89%	-4.43%	+33.02%	2.61B
ENOVIS CORPORATION	+7.79%	+11.22%	+22.07%	-46.71%	1.68B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	+1.81%	+4.56%	-23.47%	-29.50%	1.68B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	+0.48%	+3.95%	-14.40%	-17.45%	1.67B
Average	+1.45%	+4.48%	+3.66%	+4.05%	20.05B
Weighted average by Cap.	+4.13%	+2.23%	-2.76%	+24.54%

	2023	2024
Net sales	42.88M 4.48M 3.9M 3.64M 3.34M 6.29M 427M 6.4M 16.79M 213M 16.83M 16.46M 703M	57.98M 6.06M 5.27M 4.92M 4.51M 8.51M 578M 8.66M 22.71M 288M 22.76M 22.26M 950M
Net income	-209M -21.83M -18.97M -17.71M -16.26M -30.66M -2.08B -31.2M -81.81M -1.04B -82.01M -80.19M -3.42B	-95.98M -10.03M -8.72M -8.14M -7.47M -14.09M -956M -14.34M -37.59M -477M -37.68M -36.85M -1.57B
Net Debt	43.85M 4.58M 3.98M 3.72M 3.41M 6.44M 437M 6.55M 17.17M 218M 17.21M 16.83M 719M	214M 22.35M 19.42M 18.13M 16.64M 31.38M 2.13B 31.93M 83.73M 1.06B 83.93M 82.07M 3.5B